SOX8 Knockdown Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting the Notch Signaling Pathway

Table 2

Demographic and clinical characteristics of the patients with PCa and CRPC.

(a)

	SOX8 expression in PCa			SOX8 expression in CRPC
	Negative 26/45 (58%)	Positive 19/45 (42%)	value	Negative 9/35 (26%)	Positive 26/35 (74%)	value
Median of PSA (μg/L)	15.55	27.33	^a	14.93	23.33	^a
Quartiles 25-75	11.46-33.20	16.09-41.32		10.36-46.47	12.58-33.84
Gleason score			^b			^b
≤7	13/26 (50%)	12/19 (63%)		3/9 (33%)	10/26 (38%)
≥8	13/26 (50%)	7/19 (37%)		6/9 (67%)	16/26 (62%)
(New)bone metastasis	7/26 (27%)	13/19 (68%)	^c	4/9 (44%)	25/26 (96%)	^c

(b)

	Notch4 expression in PCa			Notch4 expression in CRPC
	Negative 23/45 (51%)	Positive 22/45 (49%)	value	Negative 8/35 (22%)	Positive 27/35 (78%)	value
Median of PSA (μg/L)	14.55	25.89	^a	13.84	23.33	^a
Quartiles 25-75	10.66-32.56	15.91-65.07		10.36-29.90	12.58-35.73
Gleason score			^b			^b
≤7	10/23 (43%)	10/22 (45%)		2/8 (25%)	11/27 (41%)
≥8	13/23 (57%)	12/22 (55%)		6/8 (75%)	16/27 (59%)
(New)bone metastasis	6/23 (26%)	14/22 (64%)	^c	4/8 (50%)	25/27 (93%)	^c

(c)

	Hes5 expression in PCa			Hes5 expression in CRPC
	Negative; 24/45 (53%)	Positive; 21/45 (47%)	value	Negative; 11/35 (31%)	Positive; 24/35 (69%)	value
Median of PSA (μg/L)	15.96	25.33	^a	15.31	23.54	^a
Quartiles 25-75	10.40-31.20	15.70-52.23		11.72-34.23	12.34-35.11
Gleason score			^b			^b
≤7	11/24 (46%)	8/21 (38%)		2/11 (18%)	11/24 (46%)
≥8	13/24 (54%)	13/21 (62%)		9/11 (82%)	13/24 (54%)
(New)bone metastasis	7/24 (29%)	13/21 (62%)	^c	7/11 (64%)	22/24 (92%)	^c

PSA: prostate-specific antigen; PCa: prostate cancer; CRPC: castration-resistant prostate cancer. ^aMann-Whitney test. ^bChi-square test. ^cMcNemer test. Numbers in italic font indicate statistical significance. was confirmed as statistically significant differences.